1. Home
  2. MORN vs UTHR Comparison

MORN vs UTHR Comparison

Compare MORN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MORN
  • UTHR
  • Stock Information
  • Founded
  • MORN 1984
  • UTHR 1996
  • Country
  • MORN United States
  • UTHR United States
  • Employees
  • MORN N/A
  • UTHR N/A
  • Industry
  • MORN Investment Managers
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • MORN Finance
  • UTHR Health Care
  • Exchange
  • MORN Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • MORN 12.9B
  • UTHR 14.4B
  • IPO Year
  • MORN 2005
  • UTHR 1999
  • Fundamental
  • Price
  • MORN $289.74
  • UTHR $298.16
  • Analyst Decision
  • MORN Buy
  • UTHR Buy
  • Analyst Count
  • MORN 3
  • UTHR 13
  • Target Price
  • MORN $361.67
  • UTHR $383.08
  • AVG Volume (30 Days)
  • MORN 326.4K
  • UTHR 476.5K
  • Earning Date
  • MORN 07-30-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • MORN 0.64%
  • UTHR N/A
  • EPS Growth
  • MORN 80.06
  • UTHR 18.86
  • EPS
  • MORN 8.91
  • UTHR 25.10
  • Revenue
  • MORN $2,314,200,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • MORN $7.91
  • UTHR $14.58
  • Revenue Next Year
  • MORN $8.39
  • UTHR $6.34
  • P/E Ratio
  • MORN $32.17
  • UTHR $11.88
  • Revenue Growth
  • MORN 10.11
  • UTHR 19.84
  • 52 Week Low
  • MORN $250.34
  • UTHR $266.98
  • 52 Week High
  • MORN $365.00
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • MORN 34.16
  • UTHR 52.16
  • Support Level
  • MORN $305.96
  • UTHR $291.72
  • Resistance Level
  • MORN $308.17
  • UTHR $300.37
  • Average True Range (ATR)
  • MORN 5.61
  • UTHR 6.20
  • MACD
  • MORN -2.47
  • UTHR 1.30
  • Stochastic Oscillator
  • MORN 20.86
  • UTHR 81.43

About MORN Morningstar Inc.

Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: